

Supplementary Table 1. ICD-9 codes used to identify outcomes and co-morbidities. All hereby listed codes include the corresponding sub-codes.

Prostate cancer	185									
Diabetes mellitus	250									
Hypertension	401	402	403	404	405	437.2				
Ischaemic heart disease	410	411	412	413	414					
Myocardial infarction	410									
Heart failure	428									
Stroke or transient ischaemic attack	430	431	432	433	434	435				
Chronic kidney disease	582	585	586							
Hyperlipidaemia	272.0	272.1	272.2	272.3	272.4					
Other malignancies	140	141	142	143	144	145	146	147	148	149
		150	151	152	153	154	155	156	157	158
		159	160	161	162	163	164	165	170	171
		172	173	174	175	179	179	180	181	182
		183	184	185	186	187	188	189	190	191

	192	193	194	195	196	197	198	199	200
	201	202	203	204	205	206	207	208	
	209.0	209.1	209.2	209.3					

ICD-9, *International Classification of Diseases, Ninth Revision*.

Supplementary Table 2. Summary of Main Analyses, with wHR referenced against Abiraterone Use.

	wHR (95% CI)	P-value
4P-MACE	0.71 (0.59 – 0.86)	<0.001
MI	0.57 (0.33 – 0.97)	0.040
Stroke	1.18 (0.58 – 2.39)	0.648
HF	0.43 (0.16 – 1.15)	0.091
All-cause mortality	0.71 (0.59 – 0.85)	<0.001

4P-MACE, 4-point major adverse cardiovascular events. CI, confidence interval. HF, heart failure. MI, myocardial infarction. wHR, weighted hazard ratio.

Supplementary Table 3. Multivariable Analysis for 4P-MACE, with aHR referenced against Abiraterone Use.

	aHR (95% CI)	P-value
4P-MACE	0.71 (0.60 – 0.84)	<0.001

4P-MACE, 4-point major adverse cardiovascular events. aHR, adjusted hazard ratio.CI, confidence interval.